fashion -WSS

fashion

author：explore 2025-09-06 04:38:57 - browse：67

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： More tobacco lobbyists active in statehouses

leisure time

WSS

Melinda French Gates resigns from Gates Foundation

Pfizer plans to depart BIO

Leukemia patients are helped by Syndax's new type of therapy

Congenital heart disease patients face new threat of heart failure

Getting Alzheimer's drug Leqembi to patients can be a challenge

H5N1 bird flu found in pasteurized milk: what we know

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approves world's first CRISPR

The high cost of giving birth even with insurance

Teach medical students about patients with intellectual disabilities

How to save PrEP access — and even expand it

Teach medical students about patients with intellectual disabilities

Guidelines to prevent youth baseball injuries need more muscle

CMS should re

How to save PrEP access — and even expand it

Teach medical students about patients with intellectual disabilities

hotspot

After sickle

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

More tobacco lobbyists active in statehouses

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

H5N1 bird flu found in pasteurized milk: what we know

Wikipedia

leisure time

hotspot

leisure time